Covid-19 News

  • Navid - i suspect you need to get out more.

    This is why I call you a fascist. You welcome the killing of a kid sent home without treatment. You never question this (no treatment). So you claim that the death of a kid (no section so far is available) can be used for justifying giving an experimental cancer treatment to our youngest. This is the second reason why I call you a buddy of Dr. Mengele or even a worse person, as you repeat your action with great joy.

  • He added: 'Millions of people are already dealing with the symptoms of long Covid syndrome.

    This is plain fantasy. No official data exists so far!

    Up to one in three patients who fall severely ill with coronavirus develop dangerous blood clots, it has been estimated.

    This is about 0.2% of all PCR+ cases at most!!

    I'm leaning on that the best strategy is probably to take the jab, what for the effect to vane, then get covid and have a natural infection as well.

    The problem with this is that the vaccines given today are far away to match the actual spike. So ADE effects can occur much stronger in future also if you get a classic cold!!

    As the recent Project Salus Medicare study indicates a growing number of overall COVID-19 infections are in fact breakthrough infections.

    I know from health care personal that they got the order top shut mouth about the real figures of double vaxx people in ICU & critical care...

  • I think W needs to view this. It is a useful video.


    External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

  • Typical industry response, character assassination

  • Highly Vaccinated Singapore Fighting Highest Surge in Cases:


    Highly Vaccinated Singapore Fighting Highest Surge in Cases:
    Back in 2020, Singapore was the model country for how to manage COVID-19. Unlike nations that had high case numbers and mortality rates, like the US,
    trialsitenews.com



    TrialSite Staff

    October 5, 2021

    3 Comments




    Back in 2020, Singapore was the model country for how to manage COVID-19. Unlike nations that had high case numbers and mortality rates, like the US, Singapore had the lowest mortality rate in the world. It was impressive, leaving frustrated Americans to ask, “Why didn’t we respond as Singapore did?” Fast forward to today, and after a highly successful vaccination campaign, Singapore is battling its largest surge in COVID cases ever. What went wrong?


    It’s difficult to compare country-to-country responses to a public health emergency because so much depends on wealth, the underlying age and health of a population, the relationship between a population and its government, and how much freedom a population is willing to sacrifice for a perceived “greater good.”


    Unlike medicine, which happens at the individual level, public health interventions happen at the population level, which means they are a lot trickier to implement while keeping people satisfied enough to maintain efficiency. Singapore’s early success is most likely due to a combination of factors: strict lockdowns, or what they call “circuit breakers,” mask mandates, and economic incentives for folks who had to stay home and could not work.


    The government, authoritarian leaning, punished anyone who didn’t comply, but more importantly, the people of Singapore willingly followed, as is commonplace in this society. There was little resistance. Perhaps another reason Singapore had great success earlier in the pandemic is that they have a relatively low obesity rate, and obesity significantly increases the risk of both severity and death from COVID-19. Singapore’s obesity rate is below 10%, whereas in the US, it’s above 40%. Both countries’ rates are increasing, however.


    In December of 2020, Singapore continued its streak as the model student by being the first Asian country to begin a COVID-19 vaccination campaign. It was also the first Asian country to approve both mRNA vaccines. Unlike America, Singapore used all vaccines approved for use by the World Health Organization, which includes Pfizer-BioNtech Comirnaty, Covishield and AstraZeneca, Johnson & Johnson’s Janssen, Moderna, and China’s Sinopharm and Sonvac-Coronavac. In a short time, Singapore vaccinated 80% of its population, and people were confident that things were going to get better.


    Things didn’t get better, however—they rather worsened. Currently, cases are surging in Singapore, and their death rate, while still low, is increasing. They’ve even started booster shots, much like another highly vaccinated nation, Israel, and they are increasing restrictions again. What happened?


    Perhaps it’s a case where the vaccines are significantly less effective against the more infectious Delta variant than for the “original” viral variant for which they were developed. Perhaps some vaccines in use work better than others, although we saw a similar rise in cases in Israel, where only the Pfizer vaccine was used. Perhaps there was too little naturally acquired immunity in the population due to lack of exposure from strict social distancing and lockdowns in 2020. Whatever the cause, Singapore’s sudden spike in cases following a very successful vaccination campaign is, at the least, an epidemiological mystery worth exploring. If the vaccines work, why the sudden surge?

  • Israel:: The death rate due to a huge backlog of booster induced CoV-19 cases is still high. It looks like about 70% of the these people die as the hospital ICU rate goes down in line with this. So it will take about 300 (150 booster victims) more deaths (3-4 weeks) until we get to the base line and start to see the real booster performance.

    The graphics shows about 8 booster deaths Among 20. About 45..50% of the current deaths are among 2x & 3x vaccinated some rare are new first jab victims.... (population is about 64% double vaxx)


    קורונה - לוח בקרה


    Third last line left.

  • Wyttenbach is to the only one here who seemed to have missed his Knigge manner lessons back in school… was convenient to read the posts and follow the objective discussions on pros and cons here the last day without any ranting, insulting and primitive language…. 😢

  • There are contaminants regularly found in food and medicines. The batch gets recalled, not the whole product, unless it is some universal problem.

    Thanks for your posting with evidence from an other part of the world. If you find such evidence in Germany AND Japan, it could well appear somewhere else and I would call it "universal".
    So it seems even the manufacturing process is experimental.


    This is giving confidence and trust for the jab a real boost!


    By the way here is the link to the mentioned video!:

    Death by vaccination - undeclared components of the COV19 vaccines (press conference of September 20, 2021)

    Tod durch Impfung - undeklarierte Bestandteile der COV19-Impfstoffe (Pressekonferenz v. 20.09.2021) - YouTube

  • The India vaccine terror state of Kerala (& Mizoram the small shadow), with the THH fascist no treatment regime in place, still makes up >50% of all Inida's deaths and CoV-19 cases

    https://www.mygov.in/covid-19 As of 06 October 2021!

    The Kerala death number/mio now is > 7x of poor Uttar Pradesh.


    So now for 4 months we can see it and learn from it. Vaccination does never reduce CoV-19 cases in short and mid term dimensions. (We know it since June). Vaccines only is murder and a severe violation of the of the medical ethic code that asks for a treatment lege artis.


    Last time this happened was in dark fascist WWII. Also at that time (1932..1945) most people did not know that they support fascism. The irony of today is that even the victims of WWII living in Israel do in general no treatment lege artis... So this shows that fascism is a global problem and people are not willing to understand it.

  • Thanks for your posting with evidence from an other part of the world. If you find such evidence in Germany AND Japan, it could well appear somewhere else and I would call it "universal".
    So it seems even the manufacturing process is experimental.


    This is giving confidence and trust for the jab a real boost!

    You maybe need to look at exactly from where the German evidence came? I'd bet it is the same Japanese batches that have been recalled and were highly advertised. No-one covers thi stuff up and like any food when things are contaminated they get recalled.


    In this case I doubt much harm was done, given the nature of the contamination.


    With billions of jabs some will go wrong!


    THH

  • Report: New PCR test intelligence around Wuhan suggests COVID-19 was virulent earlier than thought


    Report: New PCR test intelligence around Wuhan suggests COVID-19 was virulent earlier than thought
    The coronavirus may have been spreading through Wuhan, China much earlier than previously thought, according to an analysis of Chinese procurement records by…
    therecord.media


    The coronavirus may have been spreading through Wuhan, China much earlier than previously thought, according to an analysis of Chinese procurement records by Internet 2.0, a company that specializes in digital forensics and intelligence analysis.


    According to a report released Monday, entitled “Procuring for a Pandemic: An Assessment of Hubei Province PCR Procurement Contracts,” there was a dramatic increase in the number of Polymerase Chain Reaction, or PCR, contracts inked by Hubei Province and institutions in and around Wuhan in the second half of 2019.


    The Trump administration had long maintained, without evidence, that it was not coincidence that the virus appeared to come from a wet market not far from a lab in Wuhan that focused on the coronavirus. The Biden administration, for its part, has asked U.S. intelligence agencies to redouble their efforts to find the origin of the pandemic. The report from Internet 2.0 offers yet another thread to pull — third party data points in the form of PCR-related procurement contracts.


    “An initial view of the data depicts the dramatic increase of PCR procurement contracts in 2019,” the report says. “The increase was present in both the contract total value and the number of contracts.”


    PCR tests are the gold standard for COVID-19 virus testing and if there was spike in the use of those tests in the Spring of 2019, as the report suggests, that could mean the timeline for when the virus was actually spreading in the wild would dramatically shift: from December 2019 to as early as May 2019.


    Among other things, there was a dramatic increase in the total amount of money spent on these tests in and around Wuhan, in Hubei province, the report said. In 2015, institutions there spent about 19.1 million yuan ($2.9 million) on PCR tests. Two years later, in 2017, they spent about 29.1 million yuan and in 2018, institutions around Wuhan spent 36.7 million on these tests.


    But when analysts looked at the spending in 2019, the government contract value for PCR tests was higher than the previous two years combined: 67.4 million yuan. (The tests got more expensive, which also suggests they got pricer as demand went up, the report says.)


    A team of experts from the World Health Organization investigating the origins of the pandemic visited The Wuhan Institute of Virology back in June to see if it could link its research on coronaviruses with the pandemic. WHO’s findings have been inconclusive, though the Internet 2.0 report notes that the institute was one of the biggest purchasers of PCR tests and equipment in the second half of 2019.


    The company’s analysis is based on data collected through bidcenter.com.cn, which tracks Chinese government contracts. According to the researchers, there were 52 contracts found in 2015, and about the same number in 2016. In 2019, though, institutions like the Wuhan University of Science and Technology, the Wuhan CDC, and Hubei CDC had secured 135 contracts for PCR tests. Nearly double the number of the previous two years combined.


    The monthly breakdown of purchases offers clues, too. There was a significant increase in spending on PCR tests and equipment over the summer of 2019, starting in May, which was remarkably different from the spending patterns in previous years.


    “The full inventory of this catastrophe is still being compiled,” Robert Potter, one of the authors of the report, said in a written statement. “What is clear is that investigating the coverup of the virus still has some distance to go before it is fully understood. The data presented here gives us a strong indication that the outbreak started prior to December 2019, meaning the information gap and window for the emergence of the virus is larger than when we started this project.”


    He said they would be continuing their investigation.

  • MERCK SELLS FEDERALLY FINANCED COVID PILL TO U.S. FOR 40 TIMES WHAT IT COSTS TO MAKE

    The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense


    Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to Make
    The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense.
    theintercept.com


    A FIVE-DAY COURSE of molnupiravir, the new medicine being hailed as a “huge advance” in the treatment of Covid-19, costs $17.74 to produce, according to a report issued last week by drug pricing experts at the Harvard School of Public Health and King’s College Hospital in London. Merck is charging the U.S. government $712 for the same amount of medicine, or 40 times the price.


    Last Friday’s announcement that the new medicine cut the risk of hospitalization among clinical trial participants with moderate or mild illness in half could have huge implications for the course of the coronavirus pandemic. Because it’s a pill — as opposed to monoclonal antibodies, a comparable antiviral treatment that is administered intravenously — molnupiravir is expected to be more widely used and, hopefully, will cut the death rate. In the first 29 days of the trial, no deaths were reported among the 385 patients who received the drug, while eight of the people who received a placebo died, according to the statement put out by Merck and Ridgeback Biotherapeutics, the two companies that are jointly launching it.

    In addition to having huge implications for health, the pill could bring staggering profits to both Merck and Ridgeback Biotherapeutics. A small Miami-based company, Ridgeback licensed the medicine from Emory University in 2020 and two months later sold the worldwide rights to the drug to Merck for an undisclosed sum. Although Ridgeback remains involved in the development of the drug, some have described the deal as “flipping.”


    Like the vast majority of medicines on the market, molnupiravir — which was originally investigated as a possible treatment for Venezuelan equine encephalitis — was developed using government funds. The Defense Threat Reduction Agency, a division of the Department of Defense, provided more than $10 million of funding in 2013 and 2015 to Emory University, as research done by the nonprofit Knowledge Ecology International has revealed. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, also provided Emory with more than $19 million in additional grants.


    MOST READ


    Network of Right-Wing Health Care Providers Is Making Millions Off Hydroxychloroquine and Ivermectin, Hacked Data Reveals

    Micah Lee


    Joe Manchin Denies He Knew About Key Democratic Strategy to Pass Spending Bills

    Sara Sirota, Ryan Grim


    EPA Officials Exposed Whistleblowers Three Minutes After Receiving Confidential Complaint

    Sharon Lerner

    Yet only Merck and Ridgeback will reap the profits from the new antiviral, which according to Quartz could bring in as much as $7 billion by the end of this year. After the announcement of the encouraging clinical trial results on Friday, Merck’s stock price climbed, while stock prices of some vaccine makers sagged. Despite its initial investment, the U.S. government seems to be facing a steep markup in prices. In June, the government signed a $1.2 billion contract with Merck to supply 1.7 million courses of the medication at the $712 price. The transaction is due to take place as soon as molnupiravir receives emergency use authorization from the Food and Drug Administration.


    Reasonable Terms

    Good government advocates are pointing out that because federal agencies spent at least $29 million on the drug’s development, the government has the obligation to ensure that the medicine is affordable. “The public funded this drug, and therefore the public has some rights, including the rights you have it available under reasonable terms,” said Luis Gil Abinader, senior researcher at Knowledge Ecology International.

    In an interview on CNBC, Ridgeback co-founder Wendy Holman noted that the company asked for but “never got government funding” to help manufacture molnupiravir. A whistleblower complaint filed by Rick Bright, the former director of the Biomedical Advanced Research and Development Authority, or BARDA, in May 2020, described Ridgeback’s unsuccessful efforts “to secure approximately $100 million” from BARDA to develop the drug as a Covid-19 treatment. The company’s press release about the study results also noted that “since licensed by Ridgeback, all funds used for the development of molnupiravir have been provided by Merck and by Wayne and Wendy Holman of Ridgeback.”


    Abinader was critical of Ridgeback’s failure to acknowledge the government’s initial investment in the drug before the company acquired it. “What they want to do, apparently, is to shape the narrative about who paid for the development of this drug in order to avoid demands from the public to make it available at reasonable prices,” he said.


    In an emailed response to questions submitted to Ridgeback Biotherapeutics for this article, Davidson Goldin wrote, “Ridgeback has never received any government funding for molnupiravir and self-funded the development of this medicine for treating SARS-CoV-2 when the government did not provide financial support.” Merck did not respond to inquiries about this article.


    No Strings Attached

    Merck has promised to make molnupiravir accessible around the world and has already entered into licensing agreements with five Indian companies that manufacture generic drugs. “Merck has committed to providing timely access to molnupiravir globally, if it is authorized or approved, and plans to implement a tiered pricing approach based on World Bank country income criteria to reflect countries’ relative ability to finance their health response to the pandemic,” the company said in its announcement of the trial results on Friday. Indian companies are planning to price the drug at less than $12 for a five-day course, according to recent reports.


    In the U.S., and likely in many upper-middle-income and all high-income countries, the price will be determined by the market. Noting that the treatment may be offered to people who are not yet severely sick with Covid-19, health advocates fear that will mean some in these countries will not be able to afford the new drug. “Offering someone a $700 treatment when they don’t yet feel that ill is going to mean that a lot of people are not going to take it,” said Dzintars Gotham, a physician at King’s College Hospital in London and a co-author of the report on the pricing of molnupiravir. According to the report, pricing molnupiravir at $19.99 would allow a company a 10 percent profit margin.


    Melissa Barber, a doctoral candidate at the Harvard School of Public Health and co-author of the report on molnupiravir, said that, while its pricing is not as extreme as that of some other drugs, it will likely still place the antiviral out of reach of some who could benefit from it. “If you can’t afford medicine because it’s 1,000 times more than you can afford, or because it’s 100 times more than you can afford, it doesn’t matter,” said Barber. “Those are both bad.”


    Barber and Gotham acknowledge that the $17.74 cost of producing a five-day course of the antiviral pills is an estimate but said that the algorithm they used, and have employed to estimate the production costs for hundreds of drugs, tends to result in overestimates in the long run.

    Meanwhile, the prices that private companies charge for drugs tend to go up rather than down. “For all these deals that have happened for therapeutics or vaccines, the price has only increased as uncertainty has decreased,” she said. “One price is given and then, for the next sale, the price goes up. The price went up for other drugs and vaccines, so I would be very surprised if this price didn’t go up, too.”


    The pricing differential should be grounds to demand a better price under the Bayh-Dole Act, according to Knowledge Ecology International’s Abinader. Bayh-Dole, passed in 1980, regulates the transfer of federally funded inventions into commercial property and allows the government to “march in” and suspend the use of patents that were developed with government funding if it determines that the products are excessively priced.


    “The pressure for march-in rights around this drug is going to be huge,” predicted Abinader, who suggested that the government could use the law to lower the price of molnupiravir. “When the Biden administration negotiates another supply agreement with Merck, they should probably leverage those rights in order to get a better price,” he said.


    According to Gotham, who is based in London, the short story of molnupiravir already sums up the best and the worst of the U.S. pharmaceutical system. “It’s a great coup that the American government funded some scientists to develop antivirals,” he said. “The great tragedy is that, after their great success, they just gave it away to private industry with apparently no strings attached.”

  • Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020


    ACP Journals


    Abstract

    Background:

    Although racial/ethnic disparities in U.S. COVID-19 death rates are striking, focusing on COVID-19 deaths alone may underestimate the true effect of the pandemic on disparities. Excess death estimates capture deaths both directly and indirectly caused by COVID-19.


    Objective:

    To estimate U.S. excess deaths by racial/ethnic group.


    Design:

    Surveillance study.


    Setting:

    United States.


    Participants:

    All decedents.


    Measurements:

    Excess deaths and excess deaths per 100 000 persons from March to December 2020 were estimated by race/ethnicity, sex, age group, and cause of death, using provisional death certificate data from the Centers for Disease Control and Prevention (CDC) and U.S. Census Bureau population estimates.


    Results:

    An estimated 2.88 million deaths occurred between March and December 2020. Compared with the number of expected deaths based on 2019 data, 477 200 excess deaths occurred during this period, with 74% attributed to COVID-19. Age-standardized excess deaths per 100 000 persons among Black, American Indian/Alaska Native (AI/AN), and Latino males and females were more than double those in White and Asian males and females. Non–COVID-19 excess deaths also disproportionately affected Black, AI/AN, and Latino persons. Compared with White males and females, non–COVID-19 excess deaths per 100 000 persons were 2 to 4 times higher in Black, AI/AN, and Latino males and females, including deaths due to diabetes, heart disease, cerebrovascular disease, and Alzheimer disease. Excess deaths in 2020 resulted in substantial widening of racial/ethnic disparities in all-cause mortality from 2019 to 2020.


    Limitations:

    Completeness and availability of provisional CDC data; no estimates of precision around results.


    Conclusion:

    There were profound racial/ethnic disparities in excess deaths in the United States in 2020 during the COVID-19 pandemic, resulting in rapid increases in racial/ethnic disparities in all-cause mortality between 2019 and 2020.



    The real crime here is that the architects of our 37th world healthcare ranking still have not publicly told the public of the vitamin d deficiency in people of color and winter time deficiency. It could make the difference!!!

  • Another industry tactic, making excuses. You and jed are very forgiving of experts errors and mistakes that have cost lives! Maybe you two are the real death cult members!

  • Another industry tactic, making excuses. You and jed are very forgiving of experts errors and mistakes that have cost lives! Maybe you two are the real death cult members!

    In this case, viewing a one-off contamination event due to a broken machine when we have billions of doses of a new vaccine produced as normal, any normal person would reckon this is expected.


    Otherwise, I tend to be forgiven of mistakes made where there was no time to think things through and so much was initially not known.


    Some of the mistakes were politicians covering their own backs - or saying whatever was politically good. That is nothing to do with experts.


    Suppose you make a case for experts being bulpable as you expect (criminally negligent)?


    The only criminal behaviour I can see is people who increase vaccine hesitancy knowing the consequences.